Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease

Alzheimer's disease (AD) pathology is estimated to develop many years before detectable cognitive decline. Fluid and imaging biomarkers may identify people in early symptomatic and even preclinical stages, possibly when potential treatments can best preserve cognitive function. We previously re...

Descripción completa

Detalles Bibliográficos
Autores principales: Fagan, Anne M, Mintun, Mark A, Shah, Aarti R, Aldea, Patricia, Roe, Catherine M, Mach, Robert H, Marcus, Daniel, Morris, John C, Holtzman, David M
Formato: Texto
Lenguaje:English
Publicado: WILEY-VCH Verlag 2009
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806678/
https://www.ncbi.nlm.nih.gov/pubmed/20049742
http://dx.doi.org/10.1002/emmm.200900048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806678/
https://www.ncbi.nlm.nih.gov/pubmed/20049742
http://dx.doi.org/10.1002/emmm.200900048

Ejemplares similares